InnoCare Pharma entered a research collaboration and license agreement with Eli Lilly covering compounds against as many as five undisclosed targets. InnoCare may receive up to $100 million in upfront and near-term payments, approximately…
Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and longer follow-up from seven generalized myasthenia gravis patients. Median timed 25-foot walk improvement in SPS was 49% at Month…
Ligand committed up to $47 million to AvenCell Therapeutics. Up to $41 million will be provided in exchange for mid-single-digit to low-double-digit royalties on worldwide sales across current and future AvenCell assets, and up…
Both remigromig doses met the Week 52 noninferiority endpoint versus ranibizumab for change in best-corrected visual acuity in the 984-participant BRUNELLO trial. Merck also disclosed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and…
The FDA cleared Prime Medicine’s IND for PM647, a one-time liver-directed prime editor intended to correct the SERPINA1 E342K PiZ mutation. A global open-label Phase 1/2 study may now begin in adults with lung-predominant…
Basecamp Research announced a $140 million oversubscribed Series C led by S32, with participation from NVIDIA and other investors. It plans to expand its EDEN biological foundation models and advance an in vivo cell…
Ionis and Otsuka announced on 22 September that intrathecal ulefnersen met the prespecified primary endpoint in the placebo-controlled FUSION trial for FUS-mutated amyotrophic lateral sclerosis. A joint rank of death or permanent ventilation, rescue…
Johnson & Johnson released additional analyses of the randomized MajesTEC-3 trial in relapsed or refractory multiple myeloma after one to three prior treatment lines. At 36 months, overall survival was 83.3 percent with teclistamab…
Roche and Ionis reported that the 459-patient randomized IMAgINATION Phase 3 trial met its prespecified 37-week proteinuria endpoint in primary IgA nephropathy. Monthly subcutaneous sefaxersen significantly reduced 24-hour urine protein-to-creatinine ratio versus placebo. The…
REGENXBIO disclosed a 23 September settlement with Sarepta, the University of Pennsylvania and Catalent resolving litigation over two patents involving manufacture and sale of Elevidys. Sarepta will pay REGENXBIO $39 million within ten days…
